Skip to main content
Top
Published in: BMC Nephrology 1/2018

Open Access 01-12-2018 | Research article

Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster

Authors: Huan Yang, Musa Male, Yang Li, Ning Wang, Chenming Zhao, Shan Jin, Juncheng Hu, Zhiqiang Chen, Zhangqun Ye, Hua Xu

Published in: BMC Nephrology | Issue 1/2018

Login to get access

Abstract

Background

Substrate reduction therapy with analogs reduces the accumulation of substrates by inhibiting the metabolic pathways involved in their biosynthesis, providing new treatment options for patients with primary hyperoxalurias (PHs) that often progress to end-stage renal disease (ESRD). This research aims to evaluate the inhibition efficacy of Hydroxy-L-proline (HYP) analogs against calcium oxalate (CaOx) crystal formation in the Drosophila Melanogaster (D. Melanogaster) by comparing them with Pyridoxine (Vitamin B6).

Methods

Three stocks of Drosophila Melanogaster (W118, CG3926 RNAi, and Act5C-GAL4/CyO) were utilized. Two stocks (CG3926 RNAi and Act5C-GAL4 /CyO) were crossed to generate the Act5C > dAGXT RNAi recombinant line (F1 generation) of D. Melanogaster which was used to compare the efficacy of Hydroxy-L-proline (HYP) analogs inhibiting CaOx crystal formation with Vitamin B6 as the traditional therapy for primary hyperoxaluria.

Results

Nephrolithiasis model was successfully constructed by downregulating the function of the dAGXT gene in D. Melanogaster (P-Value = 0.0045). Furthermore, the efficacy of Hydroxy-L-proline (HYP) analogs against CaOx crystal formation was demonstrated in vivo using D. Melanogaster model; the results showed that these L-Proline analogs were better in inhibiting stone formation at very low concentrations than Vitamin B6 (IC50 = 0.6 and 1.8% for standard and dietary salt growth medium respectively) compared to N-acetyl-L-Hydroxyproline (IC50 = 0.1% for both standard and dietary salt growth medium) and Baclofen (IC50 = 0.06 and 0.1% for standard and dietary salt growth medium respectively). Analysis of variance (ANOVA) also showed that Hydroxy-L-proline (HYP) analogs were better alternatives for CaOx inhibition at very low concentration especially when both genetics and environmental factors are intertwined (p < 0.0008) for the dietary salt growth medium and (P < 0.063) for standard growth medium.

Conclusion

Addition of Hydroxy-L-Proline analogs to growth medium resulted in the reduction of CaOx crystals formation. These analogs show promise as potential inhibitors for oxalate reduction in Primary Hyperoxaluria.
Literature
1.
go back to reference Tracy CR, Pearle MS. Update on the medical management of stone disease. Curr Opin Urol. 2009;19(2):200–4.CrossRefPubMed Tracy CR, Pearle MS. Update on the medical management of stone disease. Curr Opin Urol. 2009;19(2):200–4.CrossRefPubMed
2.
go back to reference Scheinman JI, Voziyan PA, Belmont JM, Chetyrkin SV, Kim D, Hudson BG. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Urol Res. 2005;33(5):368–71.CrossRefPubMed Scheinman JI, Voziyan PA, Belmont JM, Chetyrkin SV, Kim D, Hudson BG. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Urol Res. 2005;33(5):368–71.CrossRefPubMed
3.
go back to reference Chen YH, Liu HP, Chen HY, Tsai FJ, Chang CH, Lee YJ, Lin WY, Chen WC. Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a Drosophila model for nephrolithiasis/urolithiasis. Kidney Int. 2011;80(4):369–77.CrossRefPubMed Chen YH, Liu HP, Chen HY, Tsai FJ, Chang CH, Lee YJ, Lin WY, Chen WC. Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a Drosophila model for nephrolithiasis/urolithiasis. Kidney Int. 2011;80(4):369–77.CrossRefPubMed
4.
go back to reference Hirata T, Cabrero P, Berkholz DS, Bondeson DP, Ritman EL, Thompson JR, Dow JA, Romero MF. In vivo Drosophilia genetic model for calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol. 2012;303(11):F1555–62.CrossRefPubMedPubMedCentral Hirata T, Cabrero P, Berkholz DS, Bondeson DP, Ritman EL, Thompson JR, Dow JA, Romero MF. In vivo Drosophilia genetic model for calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol. 2012;303(11):F1555–62.CrossRefPubMedPubMedCentral
5.
go back to reference Clifford-Mobley O, Sjögren A, Lindner E, Rumsby G. Urine oxalate biological variation in patients with primary hyperoxaluria. Urolithiasis. 2016;44(4):333–7.CrossRefPubMed Clifford-Mobley O, Sjögren A, Lindner E, Rumsby G. Urine oxalate biological variation in patients with primary hyperoxaluria. Urolithiasis. 2016;44(4):333–7.CrossRefPubMed
6.
9.
go back to reference Salido E, Pey AL, Rodriguez R, Lorenzo V. Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim Biophys Acta. 2012;1822(9):1453–64.CrossRefPubMed Salido E, Pey AL, Rodriguez R, Lorenzo V. Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim Biophys Acta. 2012;1822(9):1453–64.CrossRefPubMed
10.
go back to reference Lorenzo V, Torres A, Salido E. Primary hyperoxaluria. Nefrologia. 2014;34(3):398–412.PubMed Lorenzo V, Torres A, Salido E. Primary hyperoxaluria. Nefrologia. 2014;34(3):398–412.PubMed
11.
go back to reference Kogiso T, Tokushige K, Hashimoto E, Miyakata C, Taniai M, Torii N, Omori A, Kotera Y, Egawa H, Yamamoto M. Primary hyperoxaluria complicated with liver cirrhosis: a case report. Hepatol Res. 2015;45(12):1251–5.CrossRefPubMed Kogiso T, Tokushige K, Hashimoto E, Miyakata C, Taniai M, Torii N, Omori A, Kotera Y, Egawa H, Yamamoto M. Primary hyperoxaluria complicated with liver cirrhosis: a case report. Hepatol Res. 2015;45(12):1251–5.CrossRefPubMed
12.
go back to reference Lage MD, Pittman AM, Roncador A, Cellini B, Tucker CL. Allele-specific characterization of alanine: glyoxylate aminotransferase variants associated with primary hyperoxaluria. PLoS One. 2014;9(4):e94338.CrossRefPubMedPubMedCentral Lage MD, Pittman AM, Roncador A, Cellini B, Tucker CL. Allele-specific characterization of alanine: glyoxylate aminotransferase variants associated with primary hyperoxaluria. PLoS One. 2014;9(4):e94338.CrossRefPubMedPubMedCentral
13.
go back to reference Summitt CB, Johnson LC, Jonsson TJ, Parsonage D, Holmes RP, Lowther WT. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria. Biochem J. 2015;466(2):273–81.CrossRefPubMedPubMedCentral Summitt CB, Johnson LC, Jonsson TJ, Parsonage D, Holmes RP, Lowther WT. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria. Biochem J. 2015;466(2):273–81.CrossRefPubMedPubMedCentral
15.
go back to reference Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G461–9.CrossRefPubMed Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G461–9.CrossRefPubMed
16.
go back to reference Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant. 2011;26(11):3609–15.CrossRefPubMed Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant. 2011;26(11):3609–15.CrossRefPubMed
18.
go back to reference Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation. 2003;76(10):1458–63.CrossRefPubMed Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation. 2003;76(10):1458–63.CrossRefPubMed
19.
go back to reference Compagnon P, Metzler P, Samuel D, Camus C, Niaudet P, Durrbach A, Lang P, Azoulay D, Duvoux C, Bayle F, et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl. 2014;20(12):1475–85.PubMed Compagnon P, Metzler P, Samuel D, Camus C, Niaudet P, Durrbach A, Lang P, Azoulay D, Duvoux C, Bayle F, et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl. 2014;20(12):1475–85.PubMed
20.
go back to reference Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS, Investigators I. Transplantation outcomes in primary hyperoxaluria. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(11):2493–501.CrossRef Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS, Investigators I. Transplantation outcomes in primary hyperoxaluria. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(11):2493–501.CrossRef
21.
go back to reference Naderi G, Latif A, Tabassomi F, Esfahani ST. Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2. Pediatr Transplant. 2014;18(3):E69–73.CrossRefPubMed Naderi G, Latif A, Tabassomi F, Esfahani ST. Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2. Pediatr Transplant. 2014;18(3):E69–73.CrossRefPubMed
22.
go back to reference Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet. 2013;21(2):162–72.CrossRefPubMed Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet. 2013;21(2):162–72.CrossRefPubMed
23.
go back to reference Hoa BT, Hibi T, Nasuno R, Matsuo G, Sasano Y, Takagi H. Production of N-acetyl cis-4-hydroxy-L-proline by the yeast N-acetyltransferase Mpr1. J Biosci Bioeng. 2012;114(2):160–5.CrossRefPubMed Hoa BT, Hibi T, Nasuno R, Matsuo G, Sasano Y, Takagi H. Production of N-acetyl cis-4-hydroxy-L-proline by the yeast N-acetyltransferase Mpr1. J Biosci Bioeng. 2012;114(2):160–5.CrossRefPubMed
24.
go back to reference Nasuno R, Hirano Y, Itoh T, Hakoshima T, Hibi T, Takagi H. Structural and functional analysis of the yeast N-acetyltransferase Mpr1 involved in oxidative stress tolerance via proline metabolism. Proc Natl Acad Sci. 2013;110(29):11821–6.CrossRefPubMed Nasuno R, Hirano Y, Itoh T, Hakoshima T, Hibi T, Takagi H. Structural and functional analysis of the yeast N-acetyltransferase Mpr1 involved in oxidative stress tolerance via proline metabolism. Proc Natl Acad Sci. 2013;110(29):11821–6.CrossRefPubMed
26.
go back to reference Miller J, Chi T, Kapahi P, Kahn AJ, Kim MS, Hirata T, Romero MF, Dow JA, Stoller ML. Drosophila melanogaster as an emerging translational model of human nephrolithiasis. J Urol. 2013;190(5):1648–56.CrossRefPubMed Miller J, Chi T, Kapahi P, Kahn AJ, Kim MS, Hirata T, Romero MF, Dow JA, Stoller ML. Drosophila melanogaster as an emerging translational model of human nephrolithiasis. J Urol. 2013;190(5):1648–56.CrossRefPubMed
27.
go back to reference Chi T, Kim MS, Lang S, Bose N, Kahn A, Flechner L, Blaschko SD, Zee T, Muteliefu G, Bond N, et al. A Drosophila model identifies a critical role for zinc in mineralization for kidney stone disease. PLoS One. 2015;10(5):e0124150.CrossRefPubMedPubMedCentral Chi T, Kim MS, Lang S, Bose N, Kahn A, Flechner L, Blaschko SD, Zee T, Muteliefu G, Bond N, et al. A Drosophila model identifies a critical role for zinc in mineralization for kidney stone disease. PLoS One. 2015;10(5):e0124150.CrossRefPubMedPubMedCentral
28.
go back to reference Wu S-Y, Shen J-L, Man K-M, Lee Y-J, Chen H-Y, Chen Y-H, Tsai K-S, Tsai F-J, Lin W-Y, Chen W-C. An emerging translational model to screen potential medicinal plants for nephrolithiasis, an independent risk factor for chronic kidney disease. Evid Based Complement Alternat Med. 2014;2014:972958.PubMedPubMedCentral Wu S-Y, Shen J-L, Man K-M, Lee Y-J, Chen H-Y, Chen Y-H, Tsai K-S, Tsai F-J, Lin W-Y, Chen W-C. An emerging translational model to screen potential medicinal plants for nephrolithiasis, an independent risk factor for chronic kidney disease. Evid Based Complement Alternat Med. 2014;2014:972958.PubMedPubMedCentral
29.
go back to reference Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, et al. Inhibition of glycolate oxidase with dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type 1. Mol Ther. 2016;24(4):770–8.CrossRefPubMedPubMedCentral Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, et al. Inhibition of glycolate oxidase with dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type 1. Mol Ther. 2016;24(4):770–8.CrossRefPubMedPubMedCentral
30.
go back to reference Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem. 2013;288(4):2475–84.CrossRefPubMed Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem. 2013;288(4):2475–84.CrossRefPubMed
31.
go back to reference Miyata N, Steffen J, Johnson ME, Fargue S, Danpure CJ, Koehler CM. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc Natl Acad Sci U S A. 2014;111(40):14406–11.CrossRefPubMedPubMedCentral Miyata N, Steffen J, Johnson ME, Fargue S, Danpure CJ, Koehler CM. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc Natl Acad Sci U S A. 2014;111(40):14406–11.CrossRefPubMedPubMedCentral
32.
go back to reference Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E. Mutation update. Hum Mutat. 2009;30:910–7.CrossRefPubMed Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E. Mutation update. Hum Mutat. 2009;30:910–7.CrossRefPubMed
33.
go back to reference Bach TM, Takagi H. Properties, metabolisms, and applications of (L)-proline analogues. Appl Microbiol Biotechnol. 2013;97(15):6623–34.CrossRefPubMed Bach TM, Takagi H. Properties, metabolisms, and applications of (L)-proline analogues. Appl Microbiol Biotechnol. 2013;97(15):6623–34.CrossRefPubMed
34.
go back to reference Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med. 1983;309(8):445–8.CrossRefPubMed Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med. 1983;309(8):445–8.CrossRefPubMed
36.
go back to reference Katan MB. How much vitamin B6 is toxic? Ned Tijdschr Geneeskd. 2005;149(46):2545–6.PubMed Katan MB. How much vitamin B6 is toxic? Ned Tijdschr Geneeskd. 2005;149(46):2545–6.PubMed
Metadata
Title
Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
Authors
Huan Yang
Musa Male
Yang Li
Ning Wang
Chenming Zhao
Shan Jin
Juncheng Hu
Zhiqiang Chen
Zhangqun Ye
Hua Xu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2018
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-018-0980-8

Other articles of this Issue 1/2018

BMC Nephrology 1/2018 Go to the issue